Novel DX Revenue and Competitors

Location

#6666

Growjo Ranking

Fintech

Industry

Estimated Revenue & Valuation

  • Novel DX's estimated annual revenue is currently $3.2M per year.(i)
  • Novel DX's estimated revenue per employee is $104,000

Employee Data

  • Novel DX has 31 Employees.(i)
  • Novel DX grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.4M180%N/AN/A
#2
$1.8M2033%N/AN/A
#3
$26M182-3%N/AN/A
#4
$2M2216%N/AN/A
#5
$30.7M2159%N/AN/A
#6
$2.5M288%N/AN/A
#7
$40.1M287-7%$158MN/A
#8
$26.9M1882%N/AN/A
#9
$1.5M196%N/AN/A
#10
$349.4M19204%N/AN/A
Add Company

What Is Novel DX?

Lab-quality, Clinically Actionable Results in Minutes Anywhere! Novel Dx detects the genetic material of pathogens using Nucleic Acid Amplification techniques. These are the same methods that are utilized in large reference laboratories Novel Dx delivers lab-quality results in under 30 minutes so patients can be tested and treated in the same visit

keywords:N/A

N/A

Total Funding

31

Number of Employees

$3.2M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Novel DX News

2022-04-20 - Immunoassay Firm American Laboratory Products Merges with PCR ...

... immunoassay-based products but has since evolved into a producer of novel immunodiagnostic reagents for specialty testing laboratories.

2022-04-19 - NA Proactive news snapshot: Vuzix, Cloud DX, Arizona Silver Exploration, Irwin Naturals, Chesapeake Financial, Phunware UPDATE ...

NA Proactive news snapshot: Vuzix, Cloud DX, Arizona Silver Exploration, ... are waiting for transformative medicines and covers novel chemical space while...

2022-04-17 - NA Proactive news snapshot: Vuzix, Cloud DX, Arizona Silver Exploration, Irwin Naturals, Chesapeake Financial, Phunware UPDATE ...

NA Proactive news snapshot: Vuzix, Cloud DX, Arizona Silver ... waiting for transformative medicines and covers novel chemical space while...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A313%N/A
#2
$4.5M313%N/A
#3
$2.5M31-6%N/A
#4
$5.2M31-6%N/A
#5
N/A31-6%N/A